# Pharmaceuticals Bulk Drugs & Formulation — company-by-company sector analysis

> Pharmaceuticals Bulk Drugs & Formulation: Alivus Life Sciences Ltd owns the largest revenue base AND the fastest current growth.

Sector Alpha — machine-written from the numbers. Data as of 2026-08-20. Not investment advice.

## Bottom line

Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over 52 weeks and 22.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself. Alivus Life Sciences Ltd leads with revenue of ₹2,590 crore, based on 2 of 2 comparable companies through Jun 2026.

## Sector relative strength

Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over the last 52 weeks. Over 13 weeks the gap is a lead of 22.6%. 1 of 1 covered company currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Alivus Life Sciences Ltd is the strongest against the sector itself at +4.7%.

13-week sector return versus NIFTY 500: 23%
52-week sector return versus NIFTY 500: 28%
Stocks leading NIFTY: 1/1
Stocks leading sector: 1/1

Central tension: The central tension: current leadership is concentrated, so durability matters more than rank.

Companies: 2
Combined market value: ₹17.6K Cr

## 4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

1. Alivus Life Sciences Ltd (ALIVUS): 73/100 — Favorable setup; evidence 97%
   - Growth & earnings 22.6/35 | Capital efficiency 20.0/25 | Valuation 11.2/20 | Relative strength 18.7/20
   - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 7 of the last 12 weeks
   - Exact sum: 22.6 + 20 + 11.2 + 18.7 = 72.5
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2. Amanta Healthcare Ltd (AMANTA): 39/100 — Thin evidence · provisional; evidence 57%
   - Growth & earnings 5.9/35 | Capital efficiency 13.2/25 | Valuation 10.0/20 | Relative strength 10.0/20
   - Price stage: BREAKING OUT — Ahead of the benchmark five weeks or more running, with its lead holding or widening.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks
   - Exact sum: 5.9 + 13.2 + 10 + 10 = 39.1
   - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

## Market action

Alivus Life Sciences Ltd has the strongest one-year price move in Pharmaceuticals Bulk Drugs & Formulation at +48.3%. It also leads on Mansfield relative strength against NIFTY at +36.7%. 1 of 1 covered company is above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.

### Strongest one-year price performers
1. Alivus Life Sciences Ltd (ALIVUS): 48%

### Strongest relative strength versus NIFTY 500
1. Alivus Life Sciences Ltd (ALIVUS): 37%

## Pharmaceuticals Bulk Drugs & Formulation — the story behind the numbers

This is the written read behind the Pharmaceuticals Bulk Drugs & Formulation figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 19 Apr 2026, so the words are older than the numbers. 5 themes are live here.

The sector is in a transition phase where high-margin CDMO and specialty portfolios are successfully offsetting generic price erosion. While profitability is at record levels, the divergence in capex strategies and elevated working capital cycles suggest that execution on new capacity utilization will be the key differentiator in FY27.

The Pharmaceuticals Bulk Drugs & Formulation sector is witnessing a period of margin expansion, with constituents reporting EBITDA margins in the 36.4% to 37.3% range. This performance is underpinned by a transition from commodity APIs to value-added segments.

How old this read is: STALE — this read comes from our Pharmaceuticals Bulk Drugs & Formulation sector brief dated 19 Apr 2026, about 4 months ago. The page says so rather than dressing it up, and a fresh sector dive replaces it the day it runs.

### Live themes, worst first
- MEDIUM | Anticipated 5% price erosion in the generic API business due to competitive intensity. | Mitigated by next-generation process improvements and higher-margin new launches. | quoted: "On the overall growth, you can take about 5% price erosion, Tarang. The balance is the volume growth." | named for ALIVUS
- MEDIUM | Includes US tariff uncertainties and local environmental penalties. | SUDEEPPHRM passed on tariff impacts to 90% of customers; ALIVUS views its fine as a one-off. | quoted: "it became clear that only 50% of our U.S. business is subject to the announced tariff" | named for ALIVUS, SUDEEPPHRM
- LOW | China's elimination of VAT rebates on exports could increase global prices for competing products. | Management views this as supporting the narrative for an ex-China supply chain. | quoted: "China had announced the elimination of the VAT rebate. ... I think it's gone up maybe 15%-20%" | named for SUDEEPPHRM
- LOW | Need for localized stocking to improve service levels in international markets. | Commenced warehousing operations in the USA and Europe. | quoted: "the company has recently commenced warehousing operations in USA and Europe to improve service level and responsiveness." | named for SUDEEPPHRM
- LOW | Double hit from Renminbi strengthening and Rupee weakening against the USD. | 6-month contracts and a distributed supply base are in place. | quoted: "Renminbi is strengthening against the dollar and then the Rupee is weakening against the dollar. So, we have a kind of a double hit." | named for ALIVUS

Sources: our Pharmaceuticals Bulk Drugs & Formulation sector brief, 19 Apr 2026 · company earnings-call transcripts.

## Revenue Scale & Growth Durability

What the numbers say: Alivus Life Sciences Ltd is the scale leader at ₹2,590 crore, 789.4% ahead of Amanta Healthcare Ltd. Alivus Life Sciences Ltd's growth is 7.9% from a ₹2,590 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Alivus Life Sciences Ltd is the scale benchmark; Alivus Life Sciences Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Alivus Life Sciences Ltd's growth falls below Alivus Life Sciences Ltd's for two consecutive comparable reports while operating margin also compresses.

Evidence: Alivus Life Sciences Ltd · ₹2,590 crore | 789.4% versus #2 · Amanta Healthcare Ltd | 7/8 recent comparable periods | 2/2 companies · 29 observations

Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

### Revenue — largest
1. Alivus Life Sciences Ltd (ALIVUS): ₹2.6K Cr
2. Amanta Healthcare Ltd (AMANTA): ₹291 Cr

### Revenue growth — fastest growers
1. Alivus Life Sciences Ltd (ALIVUS): 7.9%
2. Amanta Healthcare Ltd (AMANTA): 7.1%

### 20-quarter Revenue history
- ALIVUS: Sep 2021 ₹562 Cr | Dec 2021 ₹522 Cr | Mar 2022 ₹514 Cr | Jun 2022 ₹490 Cr | Sep 2022 ₹509 Cr | Dec 2022 ₹541 Cr | Mar 2023 ₹621 Cr | Jun 2023 ₹578 Cr | Sep 2023 ₹595 Cr | Dec 2023 ₹573 Cr | Mar 2024 ₹537 Cr | Jun 2024 ₹589 Cr | Sep 2024 ₹507 Cr | Dec 2024 ₹642 Cr | Mar 2025 ₹650 Cr | Jun 2025 ₹602 Cr | Sep 2025 ₹588 Cr | Dec 2025 ₹673 Cr | Mar 2026 ₹689 Cr | Jun 2026 ₹640 Cr
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹68 Cr | Sep 2024 ₹67 Cr | Dec 2024 ₹68 Cr | Mar 2025 ₹72 Cr | Jun 2025 ₹65 Cr | Sep 2025 ₹71 Cr | Dec 2025 ₹74 Cr | Mar 2026 ₹77 Cr | Jun 2026 ₹69 Cr

### 20-quarter Revenue growth history
- ALIVUS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -6.7% | Sep 2022 -9.4% | Dec 2022 3.6% | Mar 2023 21% | Jun 2023 18% | Sep 2023 17% | Dec 2023 5.9% | Mar 2024 -14% | Jun 2024 1.9% | Sep 2024 -15% | Dec 2024 12% | Mar 2025 21% | Jun 2025 2.2% | Sep 2025 16% | Dec 2025 4.8% | Mar 2026 6.0% | Jun 2026 6.3%
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 -4.1% | Sep 2025 6.2% | Dec 2025 9.9% | Mar 2026 6.8% | Jun 2026 5.3%

## Operating Economics & Margin Trend

What the numbers say: Alivus Life Sciences Ltd leads both opm at 33% and margin change at +4 percentage points.

Investor read: Alivus Life Sciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Evidence: Alivus Life Sciences Ltd · 33% | 56.4% versus #2 · Amanta Healthcare Ltd | 5/8 recent comparable periods | 2/2 companies · 29 observations

Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

### OPM — highest
1. Alivus Life Sciences Ltd (ALIVUS): 33%
2. Amanta Healthcare Ltd (AMANTA): 21%

### Margin change — fastest expanders
1. Alivus Life Sciences Ltd (ALIVUS): +4.0 pp
2. Amanta Healthcare Ltd (AMANTA): −1.7 pp

### 20-quarter OPM history
- ALIVUS: Sep 2021 30% | Dec 2021 28% | Mar 2022 28% | Jun 2022 30% | Sep 2022 28% | Dec 2022 27% | Mar 2023 33% | Jun 2023 33% | Sep 2023 28% | Dec 2023 30% | Mar 2024 26% | Jun 2024 27% | Sep 2024 27% | Dec 2024 30% | Mar 2025 31% | Jun 2025 29% | Sep 2025 30% | Dec 2025 34% | Mar 2026 31% | Jun 2026 33%
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 20% | Sep 2024 21% | Dec 2024 22% | Mar 2025 26% | Jun 2025 23% | Sep 2025 21% | Dec 2025 21% | Mar 2026 19% | Jun 2026 21%

### 20-quarter Margin change history
- ALIVUS: Sep 2021 +5.4 pp | Dec 2021 −3.0 pp | Mar 2022 −8.7 pp | Jun 2022 −0.6 pp | Sep 2022 −1.6 pp | Dec 2022 −1.0 pp | Mar 2023 +5.3 pp | Jun 2023 +3.0 pp | Sep 2023 −0.2 pp | Dec 2023 +3.0 pp | Mar 2024 −7.0 pp | Jun 2024 −6.0 pp | Sep 2024 −1.0 pp | Dec 2024 0.0 pp | Mar 2025 +5.0 pp | Jun 2025 +2.0 pp | Sep 2025 +3.0 pp | Dec 2025 +4.0 pp | Mar 2026 0.0 pp | Jun 2026 +4.0 pp
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 +3.1 pp | Sep 2025 −0.1 pp | Dec 2025 −1.6 pp | Mar 2026 −6.9 pp | Jun 2026 −1.7 pp

## Profit Scale & Acceleration

What the numbers say: Alivus Life Sciences Ltd leads with ₹603 crore of TTM profit, 41× the profit of Amanta Healthcare Ltd. Alivus Life Sciences Ltd shows 21.6% growth from a ₹603 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Alivus Life Sciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Evidence: Alivus Life Sciences Ltd · ₹603 crore | 41× versus #2 · Amanta Healthcare Ltd | 7/8 recent comparable periods | 2/2 companies · 29 observations

Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

### Net profit — largest
1. Alivus Life Sciences Ltd (ALIVUS): ₹603 Cr
2. Amanta Healthcare Ltd (AMANTA): ₹15 Cr

### Profit growth — fastest growers
1. Alivus Life Sciences Ltd (ALIVUS): 22%
2. Amanta Healthcare Ltd (AMANTA): -8.3%

### 20-quarter Net profit history
- ALIVUS: Sep 2021 ₹115 Cr | Dec 2021 ₹104 Cr | Mar 2022 ₹99 Cr | Jun 2022 ₹109 Cr | Sep 2022 ₹107 Cr | Dec 2022 ₹105 Cr | Mar 2023 ₹146 Cr | Jun 2023 ₹135 Cr | Sep 2023 ₹119 Cr | Dec 2023 ₹119 Cr | Mar 2024 ₹98 Cr | Jun 2024 ₹111 Cr | Sep 2024 ₹95 Cr | Dec 2024 ₹137 Cr | Mar 2025 ₹142 Cr | Jun 2025 ₹122 Cr | Sep 2025 ₹130 Cr | Dec 2025 ₹150 Cr | Mar 2026 ₹163 Cr | Jun 2026 ₹160 Cr
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹-0 Cr | Sep 2024 ₹2 Cr | Dec 2024 ₹4 Cr | Mar 2025 ₹6 Cr | Jun 2025 ₹4 Cr | Sep 2025 ₹1 Cr | Dec 2025 ₹5 Cr | Mar 2026 ₹6 Cr | Jun 2026 ₹3 Cr

### 20-quarter Profit growth history
- ALIVUS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 7.9% | Sep 2022 -7.0% | Dec 2022 1.0% | Mar 2023 47% | Jun 2023 24% | Sep 2023 11% | Dec 2023 13% | Mar 2024 -33% | Jun 2024 -18% | Sep 2024 -20% | Dec 2024 15% | Mar 2025 45% | Jun 2025 9.9% | Sep 2025 37% | Dec 2025 9.5% | Mar 2026 15% | Jun 2026 31%
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 -46% | Dec 2025 8.2% | Mar 2026 -7.2% | Jun 2026 -5.7%

## Return On Capital Employed

What the numbers say: Alivus Life Sciences Ltd leads ROCE at 23.8%, 12.2 percentage points above Amanta Healthcare Ltd. Alivus Life Sciences Ltd has the strongest latest improvement at -0.4 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: Alivus Life Sciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Evidence: Alivus Life Sciences Ltd · 23.8% | 105.2% versus #2 · Amanta Healthcare Ltd | 2/8 recent comparable periods | 2/2 companies · 21 observations

Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

### ROCE — highest
1. Alivus Life Sciences Ltd (ALIVUS): 24%
2. Amanta Healthcare Ltd (AMANTA): 12%

### ROCE change — fastest improvers
1. Alivus Life Sciences Ltd (ALIVUS): −0.4 pp
2. Amanta Healthcare Ltd (AMANTA): −6.2 pp

### 20-quarter ROCE history
- ALIVUS: Sep 2021 31% | Dec 2021 — | Mar 2022 28% | Jun 2022 — | Sep 2022 25% | Dec 2022 — | Mar 2023 27% | Jun 2023 — | Sep 2023 27% | Dec 2023 30% | Mar 2024 26% | Jun 2024 26% | Sep 2024 21% | Dec 2024 23% | Mar 2025 21% | Jun 2025 25% | Sep 2025 21% | Dec 2025 25% | Mar 2026 21% | Jun 2026 —
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 10% | Mar 2025 16% | Jun 2025 17% | Sep 2025 12% | Dec 2025 14% | Mar 2026 9.9% | Jun 2026 —

### 20-quarter ROCE change history
- ALIVUS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −6.0 pp | Dec 2022 — | Mar 2023 −0.5 pp | Jun 2023 — | Sep 2023 +2.4 pp | Dec 2023 — | Mar 2024 −1.4 pp | Jun 2024 — | Sep 2024 −6.0 pp | Dec 2024 −6.9 pp | Mar 2025 −4.6 pp | Jun 2025 −1.0 pp | Sep 2025 +0.3 pp | Dec 2025 +2.0 pp | Mar 2026 −0.4 pp | Jun 2026 —
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 +3.4 pp | Mar 2026 −6.2 pp | Jun 2026 —

## Valuation Against Growth & Quality

What the numbers say: Alivus Life Sciences Ltd has the lowest comparable PEG at 1.17×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Evidence: Alivus Life Sciences Ltd · 1.17× | Not enough peers | 0/8 recent comparable periods | 1/2 companies · 10 observations

Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

### PEG — lowest PEG
1. Alivus Life Sciences Ltd (ALIVUS): 1.2

### P/E — lowest P/E
1. Alivus Life Sciences Ltd (ALIVUS): 27.4
2. Amanta Healthcare Ltd (AMANTA): 39.6

### 20-quarter PEG history
- ALIVUS: Sep 2021 0.0 | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 0.2 | Jun 2023 1.9 | Sep 2023 1.0 | Dec 2023 1.2 | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 1.9 | Mar 2025 — | Jun 2025 — | Sep 2025 2.1 | Dec 2025 0.8 | Mar 2026 0.8 | Jun 2026 1.2

### 20-quarter P/E history
- ALIVUS: Sep 2021 1.9 | Dec 2021 1.8 | Mar 2022 3.7 | Jun 2022 12.5 | Sep 2022 11.1 | Dec 2022 12.3 | Mar 2023 11.5 | Jun 2023 14.9 | Sep 2023 15.3 | Dec 2023 15.9 | Mar 2024 18.3 | Jun 2024 22.6 | Sep 2024 28.2 | Dec 2024 28.6 | Mar 2025 30.0 | Jun 2025 25.3 | Sep 2025 23.2 | Dec 2025 21.0 | Mar 2026 21.4 | Jun 2026 23.3
- AMANTA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 37.2 | Dec 2025 29.7 | Mar 2026 27.2 | Jun 2026 43.9


## What can make this comparison misleading?
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- Thin comparisons: Valuation have fewer than three usable current readings.

## Every company
- Alivus Life Sciences Ltd (ALIVUS) — market value ₹17.0K Cr; latest fundamentals Jun 2026
- Amanta Healthcare Ltd (AMANTA) — market value ₹607 Cr; latest fundamentals Jun 2026; includes UNVERIFIED second-feed figures

## Source standing of each company

Cross-checked: 1. Unverified: 1. Withheld: 0. Graded companies: 2.

1 of 2 companies draws at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear.

- UNVERIFIED | AMANTA | Amanta Healthcare Ltd | too little overlapping reported history to cross-check the second feed

## Methodology and freshness

Fundamentals through Jun 2026; prices through 2026-08-14.
Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable.

## Frequently asked questions

### Is the Pharmaceuticals Bulk Drugs & Formulation sector outperforming NIFTY 500?

Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over 52 weeks and 22.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself.

### Which Pharmaceuticals Bulk Drugs & Formulation company is largest by revenue?

Alivus Life Sciences Ltd leads with revenue of ₹2,590 crore, based on 2 of 2 comparable companies through Jun 2026.

### Which Pharmaceuticals Bulk Drugs & Formulation company is growing fastest?

Alivus Life Sciences Ltd has the fastest current revenue growth at 7.9%, across 2 of 2 comparable companies.

### Which Pharmaceuticals Bulk Drugs & Formulation company has the strongest 4-Factor Sector Score?

Alivus Life Sciences Ltd ranks first at 72.5/100 with 97% evidence confidence. The score prioritizes research; it is not a buy recommendation.

### Which Pharmaceuticals Bulk Drugs & Formulation company has the lowest comparable PEG?

Alivus Life Sciences Ltd has the lowest comparable PEG at 1.17, among 1 of 2 companies whose earnings and growth are steady enough for the ratio to mean anything.

### How much history does this Pharmaceuticals Bulk Drugs & Formulation comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

### How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

### Is there a Nifty Pharmaceuticals Bulk Drugs & Formulation index?

NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharmaceuticals Bulk Drugs & Formulation, this page builds its own equal-weight basket of 2 listed Pharmaceuticals Bulk Drugs & Formulation companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.

### Which are the best Pharmaceuticals Bulk Drugs & Formulation stocks in India?

Ranked by this page's four-factor score, Alivus Life Sciences Ltd places first among 2 listed Pharmaceuticals Bulk Drugs & Formulation companies, followed by Amanta Healthcare Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

### How many Pharmaceuticals Bulk Drugs & Formulation stocks are listed in India?

This comparison covers 2 listed Pharmaceuticals Bulk Drugs & Formulation companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

### Which Pharmaceuticals Bulk Drugs & Formulation company is the biggest?

Alivus Life Sciences Ltd is the largest, with trailing-twelve-month revenue of ₹2,590 crore, ahead of Amanta Healthcare Ltd at ₹291 crore. That covers 2 of 2 companies with comparable reporting through Jun 2026.

### Which Pharmaceuticals Bulk Drugs & Formulation company has the best profit margins?

Alivus Life Sciences Ltd has the highest operating margin at 33%, from 2 of 2 comparable companies. Alivus Life Sciences Ltd shows the biggest recent improvement, at +4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

### Which Pharmaceuticals Bulk Drugs & Formulation company makes the most profit?

Alivus Life Sciences Ltd earns the most, at ₹603 crore of trailing-twelve-month net profit, from 2 of 2 comparable companies. Alivus Life Sciences Ltd has the fastest profit growth at 21.6%, though growth off a small or recovering profit base overstates how much has actually changed.

### Which Pharmaceuticals Bulk Drugs & Formulation company earns the highest return on capital?

Alivus Life Sciences Ltd leads on return on capital employed at 23.8%, across 2 of 2 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

### Which Pharmaceuticals Bulk Drugs & Formulation stock is the cheapest?

On PEG — where a LOWER number is cheaper — Alivus Life Sciences Ltd screens cheapest at 1.17×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

### Is the Pharmaceuticals Bulk Drugs & Formulation sector beating the market?

Pharmaceuticals Bulk Drugs & Formulation has outperformed NIFTY 500 by 27.5% over the last 52 weeks and 22.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

### Which Pharmaceuticals Bulk Drugs & Formulation stock has the strongest price momentum?

Alivus Life Sciences Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

### Which Pharmaceuticals Bulk Drugs & Formulation company scores highest for research priority?

Alivus Life Sciences Ltd scores 72.5 out of 100 with 97% evidence confidence, from 22.6 points on growth and earnings, 20 on capital efficiency, 11.2 on valuation and 18.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

### How many Pharmaceuticals Bulk Drugs & Formulation companies does this comparison cover, and over what period?

It compares 2 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

### What is the total market cap of the Pharmaceuticals Bulk Drugs & Formulation sector?

The 2 Pharmaceuticals Bulk Drugs & Formulation companies on this page carry ₹17,632 crore of combined market value. Alivus Life Sciences Ltd is the largest at ₹17,025 crore, about 97% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20.

### How is the Pharmaceuticals Bulk Drugs & Formulation sector performing?

1 of the 1 covered Pharmaceuticals Bulk Drugs & Formulation companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 27.5% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20.

### Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

### Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.